nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.07.2021 | Short Review

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis

verfasst von: B. M. Bonora, A. Avogaro, G. P. Fadini

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread all over the world, becoming pandemic. Several studies have shown that diabetes mellitus (DM) is an independent risk factor that increases mortality and other adverse outcomes of coronavirus disease-19 (COVID-19). Studies have suggested that SARS-CoV-2 may bind dipeptidyl peptidase-4 (DPP4) for entering cells of the respiratory tract. Besides, DPP4 takes part in immune system regulation. Thus, DPP-4 inhibitors (DPP4i) may play a role against COVID-19.

Methods

We focused on the impact of DPP4i treatment on COVID-19-related outcomes in people with DM. For this purpose, we conducted a systematic review and meta-analysis to summarize the existing evidence on this topic.

Results

Retrospective observational studies provide inconsistent results on the association between use of DPP4i and outcomes of COVID-19. While two studies reported significantly lower mortality rates among patients with DM who received DPP4i versus those who did not, a series of other studies showed no effect of DPP4i or even worse outcomes. A meta-analysis of 7 studies yielded a neutral estimate of the risk ratio of COVID-19-related mortality among users of DPP4i (0.81; 95% CI 0.57–1.15).

Conclusion

In the absence of randomized controlled trials, observational research available so far provides inconclusive results and insufficient evidence to recommend use of DPP4i against COVID-19.

Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA (2020) The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J Clin Med 9(4):1225PubMedCentralCrossRef

WHO Coronavirus disease (COVID-19) Dashboard [Internet]. Available from: https://covid19.who.int/. Cited 28 Nov 2020

Fadini GP, Morieri ML, Longato E, Avogaro A (2020) Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Investig 43:867–869CrossRef

Mantovani A, Byrne CD, Zheng M-H, Targher G (2020) Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis 30(8):1236–1248PubMedPubMedCentralCrossRef

Zhu L, She Z-G, Cheng X, Qin J-J, Zhang X-J, Cai J et al (2020) Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 31(6):1068-1077.e3PubMedPubMedCentralCrossRef

Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C et al (2020) Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care 43(7):1399–1407PubMedCrossRef

Shao S, Xu Q, Yu X, Pan R, Chen Y (2020) Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther. 209:107503PubMedPubMedCentralCrossRef

Lambeir A-M, Durinx C, Scharpé S, De Meester I (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40(3):209–294PubMedCrossRef

Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y et al (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500(7461):227–231PubMedPubMedCentralCrossRef

10.

Xi CR, Di Fazio A, Nadvi NA, Patel K, Xiang MSW, Zhang HE et al (2020) A novel purification procedure for active recombinant human DPP4 and the inability of DPP4 to bind SARS-CoV-2. Molecules 25(22):5392PubMedCentralCrossRef

11.

Letko M, Marzi A, Munster V (2020) Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 5(4):562–569PubMedCrossRef

12.

Vankadari N, Wilce JA (2020) Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microb Infect 9:601–604CrossRef

13.

Qi F, Qian S, Zhang S, Zhang Z (2020) Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 526(1):135–140PubMedPubMedCentralCrossRef

14.

Kawasaki T, Chen W, Htwe YM, Tatsumi K, Dudek SM (2018) DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 315(5):L834–L845PubMedCrossRef

15.

Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G et al (2019) Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol 56(6):605–617PubMedCrossRef

16.

Bonora E, Cataudella S, Marchesini G, Miccoli R, Vaccaro O, Fadini GP et al (2020) Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory. BMJ Open Diabetes Res Care. 8(1):e001191PubMedPubMedCentralCrossRef

17.

Bonora E, Cataudella S, Marchesini G, Miccoli R, Vaccaro O, Fadini GP et al (2020) A view on the quality of diabetes care in Italy and the role of diabetes clinics from the 2018 ARNO Diabetes Observatory. Nutr Metab Cardiovasc Dis 30(11):1945–1953PubMedCrossRef

18.

Filardi T, Morano S (2020) COVID-19: is there a link between the course of infection and pharmacological agents in diabetes? J Endocrinol Invest 43(8):1053–1060PubMedPubMedCentralCrossRef

19.

Fadini GP, Morieri ML, Longato E, Bonora BM, Pinelli S, Selmin E et al (2020) Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: a case-control study. Diabetes Obes Metab 22(10):1946–1950PubMedCrossRef

20.

Sainsbury C, Wang J, Gokhale K, Acosta-Mena D, Dhalla S, Byne N et al (2021) Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study. Diabetes Obes Metab 23(1):263–269PubMedCrossRef

21.

Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I et al (2020) Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 63(8):1500–1515PubMedPubMedCentralCrossRef

22.

Pérez-Belmonte LM, Torres-Peña JD, López-Carmona MD, Ayala-Gutiérrez MM, Fuentes-Jiménez F, Huerta LJ et al (2020) Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Med 18(1):359PubMedPubMedCentralCrossRef

23.

Silverii GA, Monami M, Cernigliaro A, Vigneri E, Guarnotta V, Scondotto S, et al. (2020) Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. Nutr Metab Cardiovasc Dis

24.

Kim MK, Jeon JH, Kim SW, Moon JS, Cho NH, Han E et al (2020) The clinical characteristics and outcomes of patients with moderate-to-severe Coronavirus disease 2019 infection and diabetes in Daegu South Korea. Diabetes Metab J 44(4):602–613PubMedPubMedCentralCrossRef

25.

Yan H, Valdes AM, Vijay A, Wang S, Liang L, Yang S et al (2020) Role of drugs used for chronic disease management on susceptibility and severity of COVID-19: a large case-control study. Clin Pharmacol Ther 108(6):1185–1194PubMedCrossRef

26.

Mirani M, Favacchio G, Carrone F, Betella N, Biamonte E, Morenghi E et al (2020) Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: a case series from an academic hospital in Lombardy. Italy Diabetes Care 43(12):3042–3049PubMedCrossRef

27.

Solerte SB, D’Addio F, Trevisan R, Lovati E, Rossi A, Pastore I et al (2020) Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care 43(13):2999–3006PubMedPubMedCentralCrossRef

28.

Nafakhi H, Alareedh M, Al-Buthabhak K, Shaghee F, Nafakhi A, Kasim S (2020) Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq. Diabetes Metab Syndr 15(1):33–38PubMedPubMedCentralCrossRef

29.

Rhee SY, Lee J, Nam H, Kyoung D-S, Kim DJ (2020) Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. medRxiv. 2020.05.20.20108555

30.

Dalan R, Ang LW, Tan WYT, Fong S-W, Tay WC, Chan Y-H et al (2020) The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Hear J Cardiovasc Pharmacother

31.

Nauck MA, Meier JJ (2020) Reduced COVID-19 mortality with sitagliptin treatment? weighing the dissemination of potentially lifesaving findings against the assurance of high scientific standards. Diabetes Care 43(12):2906–2909PubMedCrossRef

32.

Gerstein HC, McMurray J, Holman RR (2019) Real-world studies no substitute for RCTs in establishing efficacy. Lancet (Lond, Engl) 393(10168):210–211CrossRef

33.

Bonora E, Monami M, Bruno G, Zoppini G, Mannucci E (2018) Attending Diabetes Clinics is associated with a lower all-cause mortality: a meta-analysis of observational studies performed in Italy. Nutr Metab Cardiovasc Dis. 28(5):431–435PubMedCrossRef

34.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (Lond Engl). 395:1033–1034CrossRef

35.

Jose RJ, Manuel A (2020) COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 8:e46–e47PubMedCrossRef

36.

Liu X, Mei T, Chen W, Ye S (2017) Comparison of antidiabetic medications during the treatment of atherosclerosis in T2DM patients. Mediators Inflamm 2017:5032708PubMedPubMedCentralCrossRef

37.

Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A et al (2012) Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 97(9):3333–3341PubMedPubMedCentralCrossRef

38.

Rizzo MR, Barbieri M, Marfella R, Paolisso G (2012) Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 35(10):2076–2082PubMedPubMedCentralCrossRef

39.

Birnbaum Y, Bajaj M, Qian J, Ye Y (2016) Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. BMJ open diabetes Res care 4(1):e000227PubMedPubMedCentralCrossRef

40.

Nomoto H, Kimachi K, Miyoshi H, Kameda H, Cho KY, Nakamura A et al (2017) Effects of 50 mg vildagliptin twice daily vs 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose. Endocr J. 64(4):417–424PubMedCrossRef

41.

Sromova L, Busek P, Posova H, Potockova J, Skrha P, Andel M et al (2016) The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 118:183–192PubMedCrossRef

42.

Tsurutani Y, Omura M, Matsuzawa Y, Saito J, Higa M, Taniyama M et al (2017) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin on atherosclerosis, β-cell function, and glycemic control in Japanese patients with type 2 diabetes mellitus who are treatment naïve or poorly responsive to antidiabetes agents: a mu. Curr Ther Res Clin Exp 84:26–31PubMedPubMedCentralCrossRef

43.

Fadini GP, Albiero M, Avogaro A (2015) Direct effects of DPP-4 inhibition on the vasculature: reconciling basic evidence with lack of clinical evidence. Vascul Pharmacol. 73:1–3PubMedCrossRef

44.

Padron S, Rogers E, Demory Beckler M, Kesselman M (2020) Republished: DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis. Drug Ther Bull 58(1):12–15PubMedCrossRef

45.

Saito T, Ohnuma K, Suzuki H, Dang NH, Hatano R, Ninomiya H et al (2013) Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors. Diabetes Res Clin Pract 102(1):e8-12PubMedCrossRef

46.

Kathe N, Shah A, Said Q, Painter JT (2018) DPP-4 inhibitor-induced rheumatoid arthritis among diabetics: a nested case-control study. Diabetes Ther Res Treat Educ Diabetes Relat Disord 9(1):141–151

Titel: Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
verfasst von: B. M. Bonora
A. Avogaro
G. P. Fadini
Publikationsdatum: 01.07.2021
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 7/2021
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-021-01515-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

Thyroid nodules in xeroderma pigmentosum patients: a feature of premature aging

Levothyroxine and insulin requirement in autoimmune polyglandular type 3 syndrome: a real-life study

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey

Was Tiepolo’s wife affected by Graves' disease?

Osteoporosis care amidst the prolonged pandemic